BIENOX 100U — Botulinum Toxin Type A (100 Units/Vial)
- 100 units of botulinum toxin type A per vial — vacuum-dried powder for reconstitution
- Average purity of 99.59% (SEC-HPLC), exceeding the 95% regulatory standard
- 900kDa neurotoxin type A complex confirmed by SDS-PAGE
- Lower neurotoxin content per vial (3.59 ng) — reduced risk of adverse events
- Phase III multicenter, double-blind, active-controlled trial: non-inferior to an established reference neurotoxin (278 patients, 20 U across 5 glabellar sites)
- Stable over 36 months of long-term stability testing; 24-month shelf life (2–8°C)
- Origin: South Korea; prescription medicine for professional use only
| 1 – 2 boxes | $33.50 / box |
| 3 – 9 boxes | $31.83 / box |
| 10 – 19 boxes | $30.15 / box |
| 20 – 29 boxes | $29.15 / box |
| 30+ boxes | Contact for quote |
What Is BIENOX 100U — Botulinum Toxin Type A (100 Units/Vial)?
A vacuum-dried botulinum toxin type A complex (100 units per vial) for the temporary improvement of moderate-to-severe glabellar lines in adult patients. Produced with advanced vacuum-drying technology that minimises potency loss and protein damage, achieving very high purity and predictable clinical performance.
BIENOX is a vacuum-dried botulinum toxin type A product — the name combines 'BIEN', from the Latin 'bene' meaning well or good, with 'OX' for botulinum toxin. Unlike conventional freeze-dried products, BIENOX is manufactured with a vacuum-drying process that shortens processing time and minimises potency loss, protein damage and inactive protein content. The 900kDa neurotoxin complex is confirmed by SDS-PAGE, and the product achieves an average purity of 99.59% by SEC-HPLC — well above the 95% regulatory criterion. Its lower neurotoxin content per vial (3.59 ng) further reduces the risk of adverse events while maintaining efficacy. BIENOX was validated in a multicenter, double-blind, randomized, parallel-group, active-controlled Phase III clinical study of 278 patients with moderate-to-severe glabellar lines, in which a total dose of 20 U injected across 5 glabellar sites proved non-inferior to an established reference neurotoxin. Long-term stability testing over 36 months showed no changes in physical or chemical properties. Manufactured in South Korea under GMP-certified facilities, BIENOX is supplied to licensed healthcare professionals only.
Specifications
| Product name | BIENOX 100U |
|---|---|
| Product type | Botulinum toxin type A neurotoxin complex — vacuum-dried powder for injection |
| Active ingredient | Clostridium botulinum toxin type A, 100 units per vial |
| Presentation | 1 vial × 100 units per box (vacuum-dried powder) |
| Purity | 99.59% average (SEC-HPLC) |
| Neurotoxin content | 3.59 ng per vial (900kDa complex confirmed by SDS-PAGE) |
| Excipients | Human serum albumin 0.5 mg, sodium chloride 0.9 mg |
| Mechanism of action | Blocks acetylcholine release at the neuromuscular junction, temporarily relaxing treated muscles |
| Indication | Temporary improvement of moderate-to-severe glabellar lines in adult patients |
| Treatment areas | Glabellar lines, forehead lines, crow's feet, masseter contouring and selected therapeutic applications |
| Onset of action | 2–5 days (typical clinical range) |
| Duration of effect | 3–6 months (dose- and area-dependent) |
| Reconstitution | 0.9% physiological saline (2.5 mL → 4 U / 0.1 mL) |
| Storage | 2–8°C, protected from light; do not freeze |
| Shelf life | 24 months (unopened) |
| Use after reconstitution | Within 24 hours at 2–8°C |
| Origin | South Korea |
Key Benefits
- Vacuum-drying technology minimises potency loss, protein damage and inactive protein during production
- Very high purity (99.59%) supports a low immunogenicity risk and consistent results
- Clinically validated — non-inferior efficacy to an established reference neurotoxin in a Phase III study
- Long-term stability: no changes in physical or chemical properties over 36 months of testing
- Reliable, predictable muscle relaxation for natural-looking results that preserve facial expression
- Versatile professional choice for glabellar lines, forehead lines, crow's feet and masseter contouring
Suggested Treatment Protocol
For professional use only. Reconstitute with 0.9% physiological saline (standard: 2.5 mL per 100 U vial, yielding 4 U per 0.1 mL). Inject the saline slowly into the vial and mix gently until the powder is fully dissolved; the solution should be clear and transparent. Use within 24 hours when stored at 2–8°C. Glabellar lines (Phase III protocol): total 20 U injected across 5 glabellar sites. Forehead lines: 10–20 U across 4–6 injection points. Crow's feet: 12–15 U per side across 3 injection points. Masseter contouring and therapeutic dosing follow individual clinical protocols. Avoid diffusion into the levator palpebrae superioris and zygomaticus major. Contraindicated in patients with hypersensitivity to any component, neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome), and during pregnancy or lactation. Avoid concomitant use of aminoglycosides or agents interfering with neuromuscular transmission.
Frequently Asked Questions
What is BIENOX 100U?
BIENOX 100U is a vacuum-dried botulinum toxin type A complex (100 units per vial) used for the temporary improvement of moderate-to-severe glabellar lines. It relaxes treated muscles by blocking acetylcholine release at the neuromuscular junction.
What makes BIENOX different from freeze-dried toxins?
BIENOX uses vacuum-drying instead of conventional freeze-drying. Vacuum drying shortens processing time and minimises potency loss, protein damage and inactive protein, achieving very high purity (99.59% average by SEC-HPLC) while preserving the 900kDa neurotoxin complex.
How is BIENOX 100U reconstituted?
Reconstitute with 0.9% physiological saline — the standard dilution for a 100 U vial is 2.5 mL, yielding 4 U per 0.1 mL. Inject the saline slowly and mix gently until fully dissolved. Use within 24 hours when stored at 2–8°C.
When do results appear and how long do they last?
Onset of action typically occurs within 2–5 days, with the full effect visible around 2 weeks. Results usually last 3–6 months depending on the treated area, dosage and individual metabolism.
What clinical evidence supports BIENOX?
BIENOX was validated in a multicenter, double-blind, randomized, active-controlled Phase III study of 278 patients with moderate-to-severe glabellar lines. A total dose of 20 U across 5 glabellar sites showed non-inferior improvement rates and patient satisfaction compared with an established reference neurotoxin.
Do you offer wholesale pricing?
Yes. Volume discounts apply: 3–9 boxes 5% off, 10–19 boxes 10% off, 20–29 boxes 13% off, and 30+ boxes contact us for a quote.
Ordered BIENOX 100U — Botulinum Toxin Type A (100 Units/Vial) for our clinic. Impressed with the average purity of 99.59% (sec-hplc), exceeding. Patients have been giving great feedback after treatments.
Please log in to leave a review.